99-Technetium Sestamibi Scanning to Predict the Efficacy of Estramustine Phosphate in Overcoming Paclitaxel Resistance in Patients with Advanced Breast Cancer
Abstract
The purpose of this research is to investigate the ability of 99-Technetium Sestamibi (Tc-99-SM) to serve as a non-invasive means of assessing the presence of clinically relevant drug resistance in patients with advanced breast cancer. Tc-99-SM is a substrate of p-glycoprotein, the transmembrane drug efflux transporter involved in classic multi- drug resistance (MDR) . Our hypothesis is that rapid clearance of Tc-99-SM correlates with the presence of functional multi-drug resistance and can be used to predict which patients will have tumors resistant to chemotherapy drugs that are MDR substrates. We have demonstrated marked variability in the tumor clearance of Tc-99-SM among patients. More importantly, we have initiated a clinical protocol that will investigate whether changes in the clearance of 99-Tc-SM observed before and after the administration of an MDR inhibitor, can predict how effective the inhibitor will be in overcoming clinical drug resistance in individual patients.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2000
- Accession Number
- ADA388884
Entities
People
- Matthew D. Volm
Organizations
- New York University